Oligonucleotide inhibitors of bcl-xL

Details Oligonucleotide inhibitors of bcl-xL Oligonucleotide inhibitors of bcl-xL

2006-07-11

2006-07-11

Epps-Ford, Janet L. (Department: 1633)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C536S024300, C536S024310, C536S024330, C536S024500

Reexamination Certificate

active

07074769

ABSTRACT:
This invention provides an antisense oligonucleotide or analog thereof comprising 10 or more contiguous bases or base analogs from the sequence of bases of sequence A, B, C, D, E, F, G, H, I, J, K, L, or M of FIG.1.This invention also provides the above-described antisense oligonucleotides, wherein the nucleotide sequence comprises nucleotide sequence A, A′, B, C, C′, D, E, E, E′, F, G, G′, H, H′, I, I′, J, K, K′, L, L′, M, or M′ of FIGS.2A and2B. This invention also provides the above-described antisense oligonucleotides, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle. This invention also provides the above-described antisense oligonucleotides, wherein the phosphate backbone comprises phosphorothioate bonds. In addition, this invention provides a method of treating cancer, comprising introducing into a tumor cell an effective amount of the the above-described antisense oligonucleotide, thereby reducing the levels of bcl-xL protein produced and treating cancer. This invention also provides the above-described methods, wherein the introducing comprises using porphyrin or lipofectin as a delivery agent. This invention also provides the above-described pharmaceutical compositions, wherein the oligonucleotide is encapsulated in a liposome or nanoparticle. This invention further provides the above-described pharmaceutical compositions, wherein the pharmaceutical composition comprises tetra meso-(4-methylpyridyl)porphine or tetra meso-(anilinium)porphine or a combination thereof.

REFERENCES:
patent: 5023243 (1991-06-01), Tullis
patent: 5107065 (1992-04-01), Schewmaker et al.
patent: 5496547 (1996-03-01), Lam et al.
patent: 5502177 (1996-03-01), Matteucci et al.
patent: 5583034 (1996-12-01), Green
patent: 5587470 (1996-12-01), Cook et al.
patent: 5593974 (1997-01-01), Rosenberg et al.
patent: 5618704 (1997-04-01), Sanghvi et al.
patent: 5670633 (1997-09-01), Cook et al.
patent: 5689052 (1997-11-01), Brown et al.
patent: 5702897 (1997-12-01), Reed et al.
patent: 5734033 (1998-03-01), Reed et al.
patent: 5776905 (1998-07-01), Gibbons et al.
patent: 5792615 (1998-08-01), Arnold et al.
patent: 5843713 (1998-12-01), Yoshida et al.
patent: WO 9307883 (1993-04-01), None
patent: WO 95/08350 (1995-03-01), None
patent: WO 9508350 (1995-03-01), None
patent: 9515400 (1995-06-01), None
patent: 9805777 (1998-02-01), None
Crooke Basic Principles of Antisense Therapeutics, Chapter 1, Antisense Research and Application, Jul. 7, 1998, Springer-Verlag, Berlin, Heidelber, New York, pp. 1-50.
Branch, A good antisense molecule is hard to find. TIBS, Feb. 1998, pp. 45-50.
Jen et al. Suppression of Gene Expression by argeted Disruption of Messenger RNA: Available Options and Current Strategies Stem Cells, 2000, vol. 18, pp. 307-319.
MJ Pollaman et al., Nature Medicine, “Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease.” Feb. 1998, vol. 4, No. 2, pp. 222-227.
X: Copies of these references were previously fowarded to Applicants during the prosecution of related application, 09/832,648.
Goodchild, J. Bioconjugate Chemistry. vol. 1, No. 3, pp. 165-187. May/Jun. 1990.
Agrawal, S., et al., Proc. Natl. Acad. Sci. U.S.A. (1988) vol. 85:7079-7083.
Antisense'97: A roundtable on the state of the industry. Nature Biotechnology 15 (Jun. 1997): 519-524.
Beaucage, S., and Caruthers, M., Tetrahedron Lett. (1981) vol. 22:1859-1862.
Cook, P.D., “Medicinal Chemistry of Antisense Oligonucleotides—future opportunities” (1991) Anti Cancer Drug Design vol. 6:585:-607.
Crooke, S.T. Vitravene—Another piece in the Mosaic. Antisense and Nucleic Acid Drug Dev. 8(1998):vii-viii.
Gewritz et al. Facilitating oligonucleotide delivery: Helping antisense deliver on it s promise. Proc. Natl. Acad. Sci. USA 93 (Apr. 1996); 3161-3163.
Ghosh, S., et al., J. Biol. Chem. (1990) vol. 265:2935-2940.
Gura, T. Antisense has growing pains. Science 270 (Oct. 1995): 575-577.
Hemken, P., et al., J. Biol. Chem. (1992) vol. 267:9948-0057.
Iverson, P., Anti-Cancer Drug Des. (1991) vol. 6:531-538.
Krajewska, M. et al. “Immunohistochemical analysis bcl-2, bax, bcl-x, and mcl-l expression in prostate cancer.” Am. J. Pathol. (1996) vol. 148:1567-1576.
Luedeke, G.H., Ziegler, Al., Stahel, R.A., and Zangemeister-Wittke, U., “Antisense oligonucleotides targeting sequences shared by the Bcl-2 and the Bcl-xL mRNA efficiently downregulate expression of both proteins and induce apoptosis of lung cancer cells.” Division of Oncology, Department of Internal Medicine, University Hospital, CH-8091 Zurich, Switzerland. (Abstract #1140 from 88 Ann. Meet. AACR, Apr. 12-16, 1997, vol. 38, (Mar. 1997), p. 171).
Milligan et al., “Current Concepts in Antisense Drug Design” Journal of Medicinal Chemistry (Jul. 9, 1993) vol. 36:1924-1937; Pollman et al., “Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease.” Nature Medicine (1998) vol. 4:222-227.
Ratajczak, et al., Proc. Natl. Acad. Sci. U.S.A. (1992) vol. 89:11823.
Rojanasakul, Y. Antisense oligonucleotide therapeutics: Drug delivery and targeting. Adv. Drug delivery rev. 18(1996: 115-131.
Stein, C.A. Keeping the biotechnology of antisense in context. Nature Biotechnology 17(Mar. 1999):209.
Stull et al. Antigene, ribozyme and aptamer nucleic acid drugs: Progress and prosepcts. Pharm. Res. 12 (Apr. 1995): 465-483.
Uhlmann, E. And Peyman A., “Antisense Oligonucleotides: A New Therapeutic Principle” Chem. Rev. (1990) vol. 90:544-579.
Wang, Z. et al., “Induction of bcl-xl by CD40 Engagement Rescues slg-induced Apoptosis in Murine B Cells”, The Journal of Immunology (1995) vol. 155:3722-3725.
Zhao, Q., et al., Antisense Research and Development (1993) vol. 3:53-66.
Zon, G., “Oligonucleotide Analogues as Potential Chemotherapeutic Agents,” Pharmaceutical Research (Nov. 9, 1988) vol. 5:539-549.
U.S. Appl. No. 09/832,633, Stein et al., filed Apr. 4, 2001.
U.S. Appl. No. 10/160,344, Stein et al., filed May 31, 2002.
Amarente-Mendes, G.P. et al. (1998), “Bcl-2 Independent BCR-ABL-mediated Resistance to Apoptosis: Protection is Correlated with Up-Regulation of Bcl-XL” Oncogene, 16:1383-13.
Leech G.H. et al. (1998), Antisense Oligodeoxynucleotides Designed to Downregulate the Expression of Bcl-XL and . . . Proc. Ann. Meet. Am. Assoc. Canc. Res. NY, 39:417.
Luedke G.H et al. (1997), Antisense Oligonucleotides Targeting Sequences Shared by the Bcl-2 and the Bcl-XL mRNA . . . Proc. Ann. Meet. Am. Assoc. Canc. Res. NY, 38:A1140.
Crooke S.T. (1998), “Basic principles of Antisense Therapeutics” Antisense research and Applications, CRC Press, pp. 1-50.

Affiliated with

Also associated with

Rating

Oligonucleotide inhibitors of bcl-xL does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oligonucleotide inhibitors of bcl-xL, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oligonucleotide inhibitors of bcl-xL will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3565754